RETRACTED: Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer – real world claim data-Reference-Cited by-同舟云学术

RETRACTED: Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer – real world claim data

Published:2018-01-31 Issue:6 Volume:24 Page:NP2-NP8
ISSN:1078-1552
Container-title:Journal of Oncology Pharmacy Practice
language:en
Short-container-title:J Oncol Pharm Pract

Author:

Leung Henry WC¹,Chan Agnes LF²,Wang Shyh-Yau³

Affiliation:

1. Department of Radiation Oncology, An Nan Hospital, China Medical University, Tainan, Taiwan

2. Department of Pharmacy, An-Nan Hospital, China Medical University, Tainan, Taiwan

3. Department of Radiology, An-Nan Hospital, China Medical University, Tainan, Taiwan

Publisher

SAGE Publications

Subject

Pharmacology (medical),Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1078155218755548

Reference16 articles.

1. Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy

2. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane

4. Development of WHO guidelines on generalized cost-effectiveness analysis

5. Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time–motion study with mixed-methods research;BMJ Open;2023-03

2. An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer;Breast Cancer Research and Treatment;2019-01-02

3. Retraction notice;Journal of Oncology Pharmacy Practice;2018-07-09